OTCMKTS:RGIN - Regenicin Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0177 0.00 (0.00 %)
(As of 02/18/2019 04:00 PM ET)
Previous Close$0.0178
Today's Range$0.0177 - $0.0177
52-Week Range$0.0020 - $0.0899
Volume1,350 shs
Average Volume32,326 shs
Market Capitalization$2.72 million
P/E RatioN/A
Dividend YieldN/A
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is based in Little Falls, New Jersey.

Receive RGIN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGIN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:RGIN



Sales & Book Value

Annual SalesN/A
Book Value($0.02) per share


Net Income$-550,000.00


Market Cap$2.72 million
OptionableNot Optionable

Regenicin (OTCMKTS:RGIN) Frequently Asked Questions

What is Regenicin's stock symbol?

Regenicin trades on the OTCMKTS under the ticker symbol "RGIN."

When is Regenicin's next earnings date?

Regenicin is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Regenicin.

Has Regenicin been receiving favorable news coverage?

News articles about RGIN stock have been trending positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regenicin earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future.

Who are some of Regenicin's key competitors?

Who are Regenicin's key executives?

Regenicin's management team includes the folowing people:
  • Mr. Randall McCoy, Chairman, CEO & Pres (Age 70)
  • Mr. John J. Weber, CFO & Director (Age 69)
  • Dr. J. Roy Nelson, Chief Science Officer (Age 71)
  • Mr. Richard Koeninger M.S, Director of Regulatory Affairs (Age 79)
  • Ms. Lauri-Ann Hahn R.N. B.S.N, Director of Clinical Trials (Age 48)

How do I buy shares of Regenicin?

Shares of RGIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regenicin's stock price today?

One share of RGIN stock can currently be purchased for approximately $0.0177.

How big of a company is Regenicin?

Regenicin has a market capitalization of $2.72 million. Regenicin employs 3 workers across the globe.

What is Regenicin's official website?

The official website for Regenicin is http://www.regenicin.com.

How can I contact Regenicin?

Regenicin's mailing address is 10 HIGH COURT, LITTLE FALLS NJ, 07424. The company can be reached via phone at 973-557-8914.

MarketBeat Community Rating for Regenicin (OTCMKTS RGIN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about Regenicin and other stocks. Vote "Outperform" if you believe RGIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel